Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Companyâ€™s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Companyâ€™s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	2.01M 1.75M 1.66M 1.51M 2.82M 193M 2.83M 19.78M 7.65M 98.04M 7.57M 7.4M 314M	P/E 2003 *	-	P/E 2004	-
Enterprise Value	2.01M 1.75M 1.66M 1.51M 2.82M 193M 2.83M 19.78M 7.65M 98.04M 7.57M 7.4M 314M	EV / Sales 2003	-	EV / Sales 2004	-
Free-Float	100%	Yield 2003 *	-	Yield 2004	-

24-10-02	Krystal Biotech, Inc. : Will it go even higher?
21-03-30	NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	CI
21-03-10	Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	CI
21-03-04	Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies	CI
21-02-26	Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	CI
21-02-22	Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology	CI
21-02-16	Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board	CI
21-02-09	Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform	CI
21-01-28	Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer	CI
20-12-10	Oncology Pharma Inc. cancelled the acquisition of acquire 50% stake in Diagnomics, Inc.	CI
20-04-06	Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating Covid-19	CI
19-12-19	Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners	CI
19-12-10	Oncology Pharma Inc. signed a Letter of Intent to acquire 50% stake in Diagnomics, Inc.	CI

22-07-12	Oncology Pharma : Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
22-06-29	Oncology Pharma : Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
22-06-06	Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022	PU
22-02-14	Oncology Pharma : Financial Statements for the period ended December 31, 2021	PU
22-02-14	Oncology Pharma : Disclosure Statement for the period ended December 31, 2021	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SOURCINGLINK.NET, INC.	-.--%	+9.50%	-	-	2.01M
ELI LILLY AND COMPANY	-0.36%	+2.82%	+50.36%	+100.80%	1,027B
JOHNSON & JOHNSON	-0.52%	+1.08%	+54.14%	+65.23%	651B
ABBVIE INC.	+0.06%	+2.65%	+18.89%	+71.45%	467B
ROCHE HOLDING AG	-1.04%	+3.95%	+36.83%	+38.71%	350B
NOVARTIS AG	-0.50%	+2.98%	+19.32%	+25.39%	268B
ASTRAZENECA PLC	+0.19%	+6.30%	+10.65%	+16.01%	257B
AMGEN INC.	+0.70%	+1.03%	+38.21%	+44.87%	205B
NOVO NORDISK A/S	+0.55%	+1.43%	-28.56%	-56.89%	190B
GILEAD SCIENCES, INC.	-0.22%	+4.46%	+32.14%	+98.54%	187B
Average	-0.13%	+2.49%	+25.77%	+44.90%	400.23B
Weighted average by Cap.	-0.27%	+2.62%	+34.71%	+61.26%

	2003	2004
Net sales	3.28M 2.86M 2.7M 2.46M 4.59M 314M 4.61M 32.21M 12.45M 160M 12.32M 12.05M 511M	1.18M 1.03M 974K 885K 1.65M 113M 1.66M 11.6M 4.48M 57.48M 4.44M 4.34M 184M
Net income	-1.52M -1.32M -1.25M -1.14M -2.13M -146M -2.14M -14.92M -5.77M -73.98M -5.71M -5.58M -237M	-1.56M -1.36M -1.29M -1.17M -2.19M -150M -2.2M -15.37M -5.94M -76.17M -5.88M -5.75M -244M
Net Debt	-1.35M -1.17M -1.11M -1.01M -1.88M -129M -1.89M -13.22M -5.11M -65.51M -5.06M -4.94M -210M	17K 14.81K 14.01K 12.73K 23.79K 1.63M 23.9K 167K 64.54K 827K 63.86K 62.44K 2.65M

SourcingLink.net, Inc. Stock OTC Bulletin Board

Stocks

US8361714053

Pharmaceuticals

Valuation: SourcingLink.net, Inc.

Latest news: SourcingLink.net, Inc.

Press Releases: SourcingLink.net, Inc.

News in other languages: SourcingLink.net, Inc.

Managers and Directors: SourcingLink.net, Inc.

Other Pharmaceuticals

Financials

Company Profile